Recruiting Lupus Studies in La Palma
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of t...
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population....
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of mo...
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult p...
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
The purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis...
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants wi...
About Lupus Clinical Trials in La Palma
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect the joints, skin, kidneys, brain, and other organs. It is more common in women and often involves periods of flares and remission. Treatment includes antimalarials, immunosuppressants, and biologics.
There are currently 6 lupus clinical trials recruiting participants in La Palma, CA. These studies are seeking a combined 2,550 participants. Research is being sponsored by Novartis Pharmaceuticals, Bristol-Myers Squibb, UCB Biopharma SRL and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Lupus Clinical Trials in La Palma — FAQ
Are there lupus clinical trials in La Palma?
Yes, there are 6 lupus clinical trials currently recruiting in La Palma, CA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in La Palma?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the La Palma research site will contact you about next steps.
Are clinical trials in La Palma free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many La Palma studies also compensate for your time and travel.
What lupus treatments are being tested?
The 6 active trials in La Palma are testing new therapies including novel drugs, biologics, and treatment approaches for lupus.
Data updated March 2, 2026 from ClinicalTrials.gov